Yehuda Handelsman, M.D.
Opted out of Medicare from January 2023 to January 2027. Internal Medicine, Endocrinology, Diabetes & Metabolism (M.D.) in Tarzana, California, licensed in CA, with an NPI issued in June 2006. Part D covered 762 prescriptions written in 2024, 65% of them generic. Novo Nordisk Inc was the largest of 28 companies reporting payments in 2025, $156,462 in all, mostly consulting fees.
Overview
| NPI | 1063453769 |
|---|---|
| Status | Active |
| Entity type | Individual |
| Credential | M.D. |
| Sole proprietor | Yes |
| NPI issued | Jun 10, 2006 |
| Last updated in NPPES | Apr 21, 2008 |
Specialties and licenses
| Taxonomy | Code | License | State |
|---|---|---|---|
| Internal Medicine, Endocrinology, Diabetes & Metabolism Primary | 207RE0101X | A44525 | CA |
Exclusion screening
| List | Result | Details |
|---|---|---|
| HHS-OIG LEIE · Oct 9, 2026 | No match | Checked by NPI and by name + state |
| North Carolina Medicaid · Nov 10, 2026 | No match | — |
| New York OMIG · Nov 10, 2026 | No match | — |
| Ohio Medicaid · Nov 10, 2026 | No match | — |
| Pennsylvania Medicheck · Nov 10, 2026 | No match | — |
| Washington HCA · Nov 10, 2026 | No match | — |
Official OIG search · How matching works ·Bulk check a roster
Medicare
| Enrollment (PECOS) | Not in the public enrollment file of Oct 1, 2026 |
|---|---|
| Opt-out | Opted out Jan 1, 2023 – Jan 1, 2027 |
| Can order and refer | Yes |
During an opt-out period the provider sees Medicare patients only under private contracts, and Medicare does not pay claims for their services.
Part D prescriptions in 2024
| Prescriptions (claims) | 762 · 1,611 30-day fills |
|---|---|
| Patients | 54 |
| Total drug cost | $244,541 |
| Generic share | 65% of claims |
Industry payments (Open Payments)
- 2025$156,462 · 169 payments from 28 companies
- 2024$104,323 · 101 payments from 19 companies
Top paying companies in 2025
| Company | Amount | Payments |
|---|---|---|
| Novo Nordisk Inc | $39,414 | 34 |
| Regeneron Pharmaceuticals, Inc. | $33,975 | 33 |
| Sanofi-Aventis U.S. LLC | $26,099 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15,796 | 18 |
| Corcept Therapeutics | $11,357 | 12 |
What the 2025 payments were for
- Consulting Fee$72,840 · 36 payments
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$68,174 · 14 payments
- Travel and Lodging$10,437 · 25 payments
- Food and Beverage$4,987 · 93 payments
- Education$24.26 · 1 payment
Receiving payments does not imply wrongdoing. What Open Payments covers ·original records
Other Internal Medicine, Endocrinology, Diabetes & Metabolism providers in Tarzana
- 1144400524
- 1396048625
- 1093710345
- 1356492060
- 1538235718
- 1487658811
All Internal Medicine, Endocrinology, Diabetes & Metabolism providers in California →